Business Wire

VA-CTA

3.10.2018 22:02:11 CEST | Business Wire | Press release

Share
CES Unveiled Paris Shines a Spotlight on Tech Innovation

The Consumer Technology Association (CTA)TM hosted the sixth annual CES Unveiled Paris today, making several announcements and shining a spotlight on the latest tech innovation. Co-located for the first time with the Mondial Paris Motor Show , CES Unveiled Paris gathered innovative exhibitors, media and industry professionals to experience the latest tech trends and products expected at CES® 2019 that will change our world for the better. Owned and produced by CTA, CES 2019 will run January 8-11, 2019 in Las Vegas, Nevada.

During the event, CTA Executive Vice President of CES Karen Chupka announced 55 French companies selected as CES® 2019 Innovation Honorees . Selected Honorees included GEOFLEX in the vehicle intelligence and self-driving category and Pixminds honored in the gaming category.

“CES Unveiled Paris highlights the innovative spirit fueling Europe’s dynamic tech market, and the French companies recognized as this year’s CES Innovation Award honorees represent the future of technology,” said Chupka. “The products and services honored today reflect the ingenuity driving our industry forward and improving the way we live, work and play.”

The remaining Innovation honorees will be announced at CES Unveiled New York on November 8, 2018. The full list of Honorees will be posted online at CES.tech and showcased at CES 2019, January 8-11.

CTA President and CEO Gary Shapiro also announced today that Dr. Lisa Su, president and CEO of AMD, will deliver a keynote at CES 2019. Dr. Su joins IBM CEO Ginni Rometty as confirmed CES 2019 keynote speakers, with additional speakers to be announced in the coming weeks.

Showcasing the latest technology products and celebrating European innovation, CES Unveiled Paris was the largest event since its inaugural debut in 2013. The event hosted 1,051 attendees from 44 countries and regions, and featured more than 76 exhibitors.

Now a full-day event, and in collaboration with the Connecting Leaders Club, CES Unveiled Paris debuted the Executive Forum on Innovation, with programming focused on emerging trends including mobility, energy and environment and artificial intelligence. More than 20 speakers were featured, including executives from Axa, Accenture, Google, Salesforce and Valeo, as they discussed the future of innovation, including trends expected at CES this January.

CES 2019 is the world’s most important and influential event. The 2019 event will showcase life-changing technology across every major industry, featuring 4,500 exhibitors across 2.75M net square feet (260K net square meters) of exhibit space. CES provides access to the very latest transformative tech such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports, machine intelligence and more.

CES is also one of the largest displays of vehicle technology in the world and was recently named as USA Today’s 10 Best Auto Shows. The 2019 show will feature more than 150 vehicle tech companies, including eight automakers, featuring the latest concept cars and connected vehicles.

Areas new to CES 2019 include the Tourism Marketplace, as well as the recently announced Resilience area, focused on technologies that keep the world healthy, safe, warm, fed and secure in the face of adversity.

Registration for CES 2019 is now open. For the latest exhibitor news and show announcements, visit CES.tech .

High-definition video b-roll of CES is available for easy download on CESbroll.com . See exclusive photos from the CES show floor, keynotes, conference sessions, events and award ceremonies in the CES photo gallery .

About CES:

CES® is the world's gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for 50 years-the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)TM , it attracts the world's business leaders and pioneering thinkers. Check out CES video highlights . Follow CES online at CES.tech and on social .

About Consumer Technology Association:

Consumer Technology Association (CTA)™ is the trade association representing the $377 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best-known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.

UPCOMING EVENTS

Contact:

Consumer Technology Association Teresa Hsu, 703-907-5259 thsu@CTA.tech www.CES.tech or Justin Siraj, 703-907-7415 jsiraj@CTA.tech www.CES.tech

Link:

ClickThru

Social Media:

https://www.facebook.com/CES

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye